NFKB1 and intrahepatic cholangiocarcinoma: Furthermore, we identified the role of a novel NF‐κB inhibitor named ICA through in vitro/in vivo and PDOs models, demonstrating that ICA plays a crucial role in inhibiting SGs formation and increasing the sensitivity to GP chemotherapy in ICC(Figure9).